<?xml version="1.0" encoding="UTF-8"?>
<ref id="B107-viruses-12-00862">
 <label>107.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Tateishi</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Fujihashi</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Yamamoto</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Hasegawa</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Ainai</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Sato</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Iho</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Yamamoto</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Maeyama</surname>
    <given-names>J.I.</given-names>
   </name>
   <name>
    <surname>Odagiri</surname>
    <given-names>T.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>CpG ODN G9.1 as a novel nasal ODN adjuvant elicits complete protection from influenza virus infection without causing inflammatory immune responses</article-title>
  <source>Vaccine</source>
  <year>2019</year>
  <volume>37</volume>
  <fpage>5382</fpage>
  <lpage>5389</lpage>
  <pub-id pub-id-type="doi">10.1016/j.vaccine.2019.07.032</pub-id>
  <pub-id pub-id-type="pmid">31345642</pub-id>
 </element-citation>
</ref>
